Sentences with phrase «identify drug candidates»

They have also established screening methods to identify drug candidates.

While PDX mice used for basic research have helped identify drug candidates, personalized mouse avatars have yet to demonstrate clear changes in the course of a person's disease, says Edward Sausville, an oncologist at the University of Maryland School of Medicine.

Later phases of the project will confirm efficacy against live Ebola virus, determine how the drug candidates block the viral machinery and develop additional tests to identify drug candidates that will inhibit not only Ebola virus, but also the related Marburg virus.

«These results identify drug candidates that may prevent activation of latent viruses in astrocytes,» Schneider concluded.

Researchers must identify drug candidates that appropriately activate the mTORC1 pathway.

Instead, Wolkowicz said his team's results demonstrate just how robust and powerful their platform is for identifying drug candidates for fighting viruses.

His goal, he adds, is to identify a drug candidate for Alzheimer's disease that pharmaceutical companies will want to evaluate.

Dr. Yin and other scientists have identified a drug candidate, MSI - 1436, that stimulates the regeneration of heart muscle in zebrafish and mice.

In only a few years, our unique approach has identified drug candidates with the potential to treat major diseases, demonstrating that regeneration could be as simple as taking a pill.

For example, the zebrafish, a common aquarium specimen, possesses the remarkable ability to rapidly replace damaged and lost body parts including limbs, heart, and nervous system, making it an ideal model for defining the genetic mechanisms of regeneration and healing and for identifying drug candidates for use in regenerative medicine.

«Through identifying drug candidates that increase SirT1, abnormalities such as creation of phosphotau and amyloid - beta associated with ApoE4 and AD could potentially be prevented,» says Rao.

Not exact matches

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

To generate a rich source of potential vaccine and drug target candidates, the team identified a set of genes that are more active in certain stages of the parasite life cycle and within the parasite's gut.

In the painstaking work of synthesizing vast numbers of compounds and identifying those that are the best candidate drugs, researchers have cultivated a capable new lab assistant: DNA.

This portion of the pharmaceutical process, in which drug candidates are identified and tested, now employs many of the latest findings in genomics and proteomics.

Now the researchers set out to identify markers of HD in non-neural tissues that could be used to track the progression of the disease and its response to P110 or other candidate drugs.

Such research may help scientists understand the mechanisms that underlie aging and identify promising drug candidates that mimic the health - promoting effects of caloric restriction, says NIA's Felipe Sierra.

Instead of systematically testing the effects of known compounds — the pharmaceutical industry's basic model for more than a century — scientists can now investigate backward, combing through genomic data to find links between specific genotypes and diseases and then screening drug data to identify therapeutic candidates.

«Scientists identify promising drug candidate to treat chronic itch, avoid side effects.»

All the drug candidates that did not bind to the protein were thereby removed; the ones that «stuck» to the protein remained in the sample, and could then be identified via their DNA barcodes.

Exploiting the same pre-clinical model used for their studies, the researchers are testing the efficacy of this kind of drug candidates against cancer stem cells, and the possibility of identifying combination regimens with standard chemotherapies with minimized toxic effects, with the perspective of their possible application for the treatment of human breast cancer.

His team looked at an experimental drug called PTC124, which the firefly luciferase assay had identified as a promising candidate for treating stop - sign forms of cystic fibrosis and which is now being tested in clinical trials.

Then, through a survey of more than 1,100 drug candidates (all FDA - approved), they identified a short list of drugs likely to convert the abnormal transcriptional signature of a tumor to a more normal one.

Cross and his team are screening drug compounds against the virus but have yet to identify serious candidates.

«This remarkable team of scientists combined NCATS» expertise in drug screening and development with Mt. Sinai's expertise in Ebola virology to rapidly identified candidate treatments for Ebola infection.»

Draper's human organ system should be able to identify effective drugs and ineffective ones early in the drug discovery process, allowing developers to refocus resources on the strong candidates earlier and end unproductive research earlier, minimizing costs, Borenstein said.

The new blood test will initially be used to identify those people with mild cognitive impairment who are likely to get Alzheimer's disease and so might be good candidates for clinical trials to find drugs that halt disease progression.

While the goal of precision medicine is to identify drugs that selectively affect disease - causing biomolecules, the process has typically involved time - consuming and expensive high - throughput screens to test millions of potential drug candidates to identify those few that affect the target of interest.

«Tuberculosis (TB) remains a major global health problem and identifying new drug targets and candidate drugs is a major priority,» said David S. Perlin, Executive Director and Professor at the Public Health Research Institute and Rutgers Regional Biocontainment Laboratory at the International Center for Public Health at Rutgers New Jersey Medical School in Newark.

The map could be useful for working out how much of a drug's effect is due to a placebo response in clinical trials and for identifying good candidates for placebo therapy.

Furthermore, parasites lacking the plasmepsins could potentially be used to screen candidate drugs to identify additional anti-malaria compounds.

Scientists at the MDI Biological Laboratory have also identified two drug candidates for the treatment of chemotherapy - induced peripheral neuropathy, a painful, disabling condition that affects at least 20 million Americans.

In just three years and with minimal financial investment, MDI Biological Laboratory scientists have identified three drug candidates.

This can help identify new molecules likely to inhibit certain therapeutic targets and to lead to novel drug candidates.

Our technology enables us to both identify a wide spectrum of drug candidates and analyze pre-clinical efficacy at an unprecedented scale.

Up the road in Bar Harbor, MDI Biological Laboratory and its spinout company, Novo Biosciences, said they have identified a potential drug candidate derived from a shark that may restore heart muscle function after a heart attack.

In Bar Harbor, MDI Biological Laboratory and its spinout company, Novo Biosciences, said they have identified a potential drug candidate derived from a shark that may restore heart muscle function after a heart attack.

The aim of this collaboration is to identify innovative drug candidates and biomarkers for immunotherapy of various types of cancer, starting from patient tumor derived material.

Quantitative proteomics can also be applied to identify major candidates of proteins targets and mechanism of action by specifically designed experiments using multiple drug / compounds in addition to that / those of interest and probing drug / compound - specific proteome responses to a treatment.

Carmot is applying an innovative technology, Chemotype Evolution, to overcome the limitations of conventional discovery technologies and identify superior drug candidates for challenging therapeutic targets.

To date, a screen of the collection of FDA - approved drugs in the Prestwick Library has identified a handful of potential candidates which have demonstrated effectiveness at lowering secretion of IL - 6, a component of SASP whose concentration tends to rise systemically with aging and here used as a preliminary marker of SASP as a phenotype.

Carmot is applying a transformative technology, Chemotype Evolution, to overcome the limitations of conventional discovery technologies and to identify superior drug candidates for challenging therapeutic targets.

A follow - up structure - based discovery campaign to develop safer opioids identified PZM21 as both a potential drug candidate and experimental tool to find other safer opioids.

Once utility of Foldit for fragment - based drug design is proven, candidate receptors for new puzzles will be identified in collaboration with Eli Lilly.

An open - source content management system then would search through upwards of a billion drug combinations to find those with the greatest potential to inhibit a given tumor, or a billion hypothetical compounds to identify candidates for new drug development.

Based on basic transcriptional studies of midbrain dopamine neurons, Dr. Kim's lab identified the orphan nuclear receptor Nurr1 as a potential drug target of Parkinson's disease (PD) to develop novel drug candidates for neuroprotective and mechanism - based therapeutics.

Their contributions to the yeast community include physical mapping methods, synthetic lethality screen approaches for identifying cross-species candidate genes as potential cancer drug targets, and a widely used set of vectors and yeast host strains that have been instrumental in work that has led to countless discoveries in recent decades.

Combined with our structures, the screening data is enabling us to identify potential chemical selectivity cues that can be used for structure - guided design of selective anti-parasitic drug candidates.

Phenotypic screening of small molecule libraries using iPSC - based models to identify novel drug candidates and disease mechanisms.

Researchers identify a new drug target in leukemia and creation of a candidate drug that hits the target...